302 related articles for article (PubMed ID: 27389485)
1. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
De Vooght KM; Oostendorp M; van Solinge WW
Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
[TBL] [Abstract][Full Text] [Related]
2. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
[TBL] [Abstract][Full Text] [Related]
3. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab: Therapeutic asset, biological trap!
Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
[TBL] [Abstract][Full Text] [Related]
5. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
Lancman G; Arinsburg S; Jhang J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richter J; Chari A
Front Immunol; 2018; 9():2616. PubMed ID: 30498492
[TBL] [Abstract][Full Text] [Related]
6. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
7. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
[TBL] [Abstract][Full Text] [Related]
8. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
9. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
Mei Z; Wool GD
Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
[TBL] [Abstract][Full Text] [Related]
10. The Challenges of Daratumumab in Transfusion Medicine.
Dizon MF
Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
12. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
[TBL] [Abstract][Full Text] [Related]
13. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
14. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
Anani WQ; Marchan MG; Bensing KM; Schanen M; Piefer C; Gottschall JL; Denomme GA
Transfusion; 2017 Jun; 57(6):1470-1479. PubMed ID: 28150308
[TBL] [Abstract][Full Text] [Related]
15. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
[TBL] [Abstract][Full Text] [Related]
16. How do I work up pretransfusion samples containing anti-CD38?
Anani WQ; Duffer K; Kaufman RM; Denomme GA
Transfusion; 2017 Jun; 57(6):1337-1342. PubMed ID: 28474469
[TBL] [Abstract][Full Text] [Related]
17. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
Song J; Fu R
J Clin Lab Anal; 2021 Dec; 35(12):e23832. PubMed ID: 34752645
[TBL] [Abstract][Full Text] [Related]
18. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
[TBL] [Abstract][Full Text] [Related]
19. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
Ye Z; Wolf LA; Mettman D; Plapp FV
Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
[TBL] [Abstract][Full Text] [Related]
20. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
